Trials / NCT06375239
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Recruiting now Observational Natural history / observational
- Sponsor
- Ray Therapeutics, Inc.
- Treatment
- Not listed
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy from Age-related Macular Degeneration, X-lined Retinoschisis, Retinal Dystrophies
- Ages
- 18 Years to no upper limit
- Enrollment
- 120 participants
- Started
- 2024-04-05
- Main results expected
- 2026-04-30
- Results posted
- Not yet
- Record last updated
- 2025-01-08
What the study is testing
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.
The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.
The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.
Where it runs
United States (1)
- Vision Research and Assessment Institute, Irvine, California (recruiting now)